Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
21 participants
INTERVENTIONAL
2016-03-31
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An optional study day (visit 5) will be used to assess the degree of lipolysis in Lipid emulsion 5 (LE5) and Lipid emulsion 6 (LE6). This study day is a randomized, single blinded study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Physical Properties of Lipid Emulsions on Gastrointestinal Function
NCT01253005
Effects of Emulsification and Lipid Droplet Size on Postprandial Metabolic Responses
NCT02789683
Cross-linked Emulsion Study
NCT01333020
THE IMMUNOLOGICAL EFFECTS AND METABOLIC TOLERANCE OF LIPID INFUSION IN PATIENTS WITH CIRRHOSIS.
NCT02381769
SMOFLipid in Patients Who Are Intralipid Intolerant
NCT03054948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The participants (n=17) will be randomized at screening to receive 3 of the 4 lipid emulsions (LE).
On each of the three study days subjects will receive 200 mL of a lipid emulsion. MRI scans will be performed at regular intervals over a period of 3.5 h. Blood samples (for GI peptide hormone analysis) will also be taken at regular intervals until 5 h post LE ingestion. Further, 13C breath test samples will be obtained from participants every 10 min until 5 h post ingestion of LE. Throughout the entire 5 h study period participants will be asked to score their visceral sensation in relation to satiation. Once the technical section of the study is complete the participant will be provided with an ad libitum buffet from which they can consume as much or a little of the food options provided in the buffet.
Optional study day: After the main study is complete and the MRI data has been analyzed the study will be unblinded. This will enable the investigators to optimize an MR imaging and gastric content sampling schedule for LE5 and LE6. The participants (n=17) will be randomized and 10 subjects will then be given the opportunity to participate in the optional study day. The optional study day is single blinded and consists of 1 extra visit and is of a maximum 3 h duration. No bloods, breath test samples or visceral sensation scores will be taken. Subjects will arrive fasted and a nasogastric tube will be positioned. 200 mL of either LE5 or LE6 containing the 13C breath test marker will then be infused. MR imaging will continue at defined intervals until maximum of 3 h. In total five gastric content samples of 5 mL will be taken with the nasogastric tube.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lipid emulsion: visit 2
One of four randomly assigned lipid emulsions
Lipid emulsion
1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
Lipid emulsion: visit 3
One of four randomly assigned lipid emulsions
Lipid emulsion
1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
Lipid emulsion: visit 4
One of four randomly assigned lipid emulsions
Lipid emulsion
1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lipid emulsion
1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
Lipid emulsion
1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
Lipid emulsion
1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
Exclusion Criteria
* History of GI, cardiorespiratory (including arterial
* hypertension), hematologic, renal, atopic, alimentary or psychiatric disorder, panic attacks, diabetes
* Prior abdominal surgery other than uncomplicated appendectomy or hernia repair
* Requiring medication that might alter gut function, including calcium channel blockers, prokinetics, macrolide antibiotics
* Presence of metallic implants, devices or metallic foreign bodies
* Pregnancy and lactation (female participants of child bearing age will receive a pregnancy test prior to study)
* Claustrophobia
* Regular smoking
* A history of drug or alcohol abuse
* A history of food allergies or intolerances
* Uncertainty about the willingness or ability of the participant to comply with the protocol requirements
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Steingötter, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Zurich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Gastroenterology and Hepatology, University Hopsital Zurich
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BASEC 2015-00032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.